Release date: October 17, 2018
Expiration date: October 16, 2019
Estimated time to complete activity: 0.75 hours
Acute myelogenous leukemia (AML) is a disease of older adults, with a median age of presentation of 67 years; only 5-10% of patients are alive at 5 years. Traditionally older patients have not received intensive induction chemotherapy to avoid toxicities, yet current research shows fit patients treated with intensive chemotherapy have better outcomes than patients with no treatment.
The goal of this program is to close existing cancer clinician competency gaps regarding new data on investigational agents for AML along with evolving evidence-based guidelines and current understanding of treatment outcomes among older patients with AML. Hematology care teams will receive updates on current treatment treatments, the new data on investigational agents for AML, and how to make risk-based decisions among older patients with AML.L.
This activity is intended for hematologists, hematology Nurse Practitioners (NPs) and Physician Assistants (PAs) and oncology nurses engaged in the care of patients with acute myelogenous leukemia (AML).
At the conclusion of these educational initiatives, participants should be able to:
- Assess clinical data on newly approved agents for relapsed/refractory AML
- Select appropriate treatment for AML according to patient risk group
- Integrate evidence-based guidelines into practice to treat patients with AML guided by molecular and cytogenetic and testing and patient-specific characteristics
Thomas W. LeBlanc, MD
Associate Professor of Medicine
Duke Cancer Institute
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Carevive Systems, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Medical Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. The maximum number of Pharmacotherapy contact hours awarded for Advanced Practice Registered Nurses is 0.5 contact hours.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related material that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Thomas LeBlanc, MDRoyalty, UpToDate, Inc., Consulting Fees, Amgen, Herron, Helsinn, Otsuka; Speaker Bureau, Celgene, Contracted Research, AstraZeneca, Seattle Genetics.
Planners and Managers
The PIM planners and managers have nothing to disclose. The Carevive planners and managers have nothing to disclose.
The following Carevive Systems, Inc. planners and managers reported the following: Timothy J. DiChiara, PhD, Consulting Fees, Daiichi Sankyo, Inc.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CNE credit for this activity. During the period October 17, 2018 through October 16, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the posttest and evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 13497. Upon registering and successfully completing the posttest with a score of 50% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year. If you have questions regarding obtaining your certificate or the accreditation of this activity, please contact PIM at www.pimed.com.
Hardware and Software Requirement
- A computer with an internet connection
- A PDF viewing software: Adobe Acrobat Reader or Apple Preview
- Internet Browser: Latest versions of Internet Explorer, Firefox, Safari, or any other W3C standards compliant browser
- Additional Software: PowerPoint, Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/ or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There is no fee for this educational activity.
This activity is supported by independent educational grants from AbbVie Inc., Astellas Scientific and Medical Affairs, Inc., Celgene Corporation and Jazz Pharmaceuticals.